ELISA/assay

Mouse Apolipoprotein B, APOB ELISA Kit

MBS937790

24-Strip-Wells (LIMIT 1)

240 USD

ELISA Kit

Mouse Apolipoprotein B, APOB ELISA Kit

[Apolipoprotein B]

[Mouse Apolipoprotein B-100 (APOB) ELISA kit; Mouse Apolipoprotein B-100 (APOB)]

[apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen); apolipoprotein B]

[APOB]

[APOB; APOB; FLDB; LDLCQ4; Apo B-100; Apo B-48]

APOB_HUMAN

Mouse

4563

This assay has high sensitivity and excellent specificity for detection of mouse apo-A5. No significant cross-reactivity or interference between mouse apo-A5 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Tissue Homogenates. Assay Type: Competitive. Detection Range: 31.2 pg/ml-2000 pg/ml. Sensitivity: 15.6pg/ml

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay: This assay employs the competitive inhibition enzyme immunoassay technique. The microtiter plate provided in this kit has been pre-coated with apo-A5. Standards or samples are added to the appropriate microtiter plate wells with Horseradish Peroxidase (HRP) conjugated antibody preparation specific for apo-A5. The competitive inhibition reaction is launched between with pre-coated apo-A5 and apo-A5 in samples. A substrate solution is added to the wells and the color develops in opposite to the amount of apo-A5 in the samples. The color development is stopped and the intensity of the color is measured.

105990532

NP_000375.2

NM_000384.2

P04114

515,605 Da

Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Pathway (477135)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

APOB: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Defects in APOB are a cause of familial hypobetalipoproteinemia type 1 (FHBL1). A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB). FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Protein type: Secreted; Secreted, signal peptide; Carrier. Chromosomal Location of Human Ortholog: 2p24-p23. Cellular Component: Golgi apparatus; extracellular space; endoplasmic reticulum membrane; chylomicron; intracellular membrane-bound organelle; cell soma; endoplasmic reticulum lumen; early endosome; cytoplasm; plasma membrane; extracellular region; endosome membrane; cytosol; actin cytoskeleton. Molecular Function: heparin binding; protein binding; low-density lipoprotein receptor binding; cholesterol transporter activity; phospholipid binding. Biological Process: lipoprotein catabolic process; phototransduction, visible light; response to lipopolysaccharide; response to carbohydrate stimulus; post-embryonic development; response to selenium ion; triacylglycerol catabolic process; retinoid metabolic process; transmembrane transport; nervous system development; cholesterol metabolic process; receptor-mediated endocytosis; cholesterol transport; in utero embryonic development; regulation of cholesterol biosynthetic process; response to virus; cholesterol efflux; lipoprotein metabolic process; sperm motility; cholesterol homeostasis; fertilization; lipoprotein transport; lipoprotein biosynthetic process; artery morphogenesis; spermatogenesis; blood coagulation; triacylglycerol mobilization; leukocyte migration. Disease: Hypercholesterolemia, Autosomal Dominant, Type B; Hypobetalipoproteinemia, Familial, 1

24-Strip-Wells (LIMIT 1)

240 USD

48-Strip-Wells

350

96-Strip-Wells

495

5x96-Strip-Wells

2105

10x96-Strip-Wells

3975